Regeneron Pharmaceuticals heads into its June 12 earnings report with analysts cutting price targets across the board and the stock nursing a 14% loss over the past month.
The analyst picture is the clearest signal of the week, and it is unambiguously one of downward revision. Following the Q1 print on April 29, virtually every firm that covers the stock trimmed its target on May 18. JPMorgan cut from $950 to $850 while keeping Overweight. Citigroup went further, downgrading from Buy to Neutral and dropping its target from $900 to $700. Leerink Partners also downgraded, moving to Market Perform with a $641 target. Canaccord, BMO, Truist, Piper Sandler, Wells Fargo, and RBC all maintained their ratings but lowered their numbers by meaningful amounts. The consensus mean target now sits around $833, still roughly 38% above the current price of $602.92 — but the direction of travel is what matters, and it has been pointing lower for two weeks straight.
The bull case rests on Dupixent's commercial durability and anticipated second-half pipeline milestones. The bear case centres on the lack of near-term pipeline catalysts, competitive threats to both Eylea and Dupixent, and last year's disappointing LAG-3 readout. That failure removed a meaningful optionality driver. With Dupixent exclusivity timelines drawing more attention, the bears have a cleaner narrative than they did six months ago. Valuation is not obviously stretched at a trailing P/E near 12 and EV/EBITDA around 7.5 — both of which have actually drifted lower over the past 30 days as the stock has sold off — but a de-rating in expectations has clearly taken hold.
Short positioning, by contrast, tells a much quieter story. Short interest dropped roughly 15% over the week to 2.8% of the free float, a level that signals no meaningful conviction from the bear side on the borrow side. Shares available to borrow are effectively unconstrained, and the cost to borrow remains negligible at around 0.5%. The ORTEX short score has eased from around 37 in late May to 34.4 now, drifting in the wrong direction for those looking for a short-squeeze narrative. This is simply not a heavily shorted name, and there is no borrow squeeze pressure in sight.
Options positioning adds an interesting twist. Traders have shifted noticeably toward calls relative to recent habit. The put/call ratio fell to 0.94, more than two standard deviations below its 20-day average of 1.03 — the most call-heavy reading in months, and a marked reversal from mid-May when the ratio hit a 52-week high of 1.13. That swing is notable: even as analysts were cutting targets on May 18, options traders were beginning to rebuild call exposure. Whether that reflects hedging unwinds, speculative positioning ahead of June 12, or genuine optimism about the upcoming print, the options market has become less defensive than at any point in the past several weeks.
Peer performance adds context. Close correlates GILD and VRTX both fell roughly 4–5% on the week, in line with REGN's 5% decline, suggesting sector-wide pressure rather than a company-specific dislocation. AMGN held up better, down only 2.3%, while CTOR dropped over 9%. The broad biotech tone has been weak, and REGN is moving with the group rather than against it.
The June 12 print is the obvious focal point. After the last Q1 report triggered a 3.4% single-day drop and a 1.5% five-day decline, and the prior quarter saw a sharper 7.8% one-day move, the pattern of post-earnings weakness is worth tracking. Whether the Street's newly revised, lower targets prove sufficient to reset expectations — or whether the call-heavy options positioning reflects genuine anticipation of a beat — is what the next two weeks will answer.
See the live data behind this article on ORTEX.
Open REGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
